Drug intelligence / Profile preview

68Ga-AKY-2519

Development stage: Unknown
Lead developer: Aktis Oncology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

68Ga-AKY-2519 is a B7-H3-targeted miniprotein radioconjugate being developed by Aktis Oncology for PET/CT imaging in patients with advanced solid tumors. As the imaging companion to the therapeutic alpha-radiopharmaceutical [225Ac]Ac-AKY-2519, it utilizes the positron-emitting isotope gallium-68 to visualize and quantify the expression of B7-H3 (CD276), a protein frequently overexpressed in various cancers including prostate and lung cancer. The agent is designed using Aktis' proprietary isotope-agnostic miniprotein platform, which aims to provide high tumor penetration and rapid clearance, optimizing the therapeutic index for its companion treatment.

Other names: [68Ga]Ga-AKY-2519Gallium-68 AKY-2519Gallium68 AKY-2519Gallium 68 AKY-2519

Targets

B7-H3

Beyond the preview

Go deeper on 68Ga-AKY-2519.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-AKY-2519.

Explore the full profile